{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:12:09Z","timestamp":1780758729635,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejogrb.2021.11.008","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T11:01:13Z","timestamp":1636628473000},"page":"98-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?"],"prefix":"10.1016","volume":"269","author":[{"given":"Wiebren A.A.","family":"Tjalma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaques","family":"van Heerden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Van den Wyngaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2021.11.008_b0005","first-page":"107","article-title":"HPV negative cervical cancers and primary HPV screening","volume":"10","author":"Tjalma","year":"2018","journal-title":"Facts Views Vis Obgyn."},{"key":"10.1016\/j.ejogrb.2021.11.008_b0010","first-page":"101","article-title":"HPV vaccination coverage in the federal state of Belgium according to regions and their impact","volume":"10","author":"Tjalma","year":"2018","journal-title":"Facts Views Vis Obgyn."},{"issue":"5","key":"10.1016\/j.ejogrb.2021.11.008_b0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1470-2045(11)70078-X","article-title":"Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study","volume":"12","author":"Kocken","year":"2011","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ejogrb.2021.11.008_b0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/LGT.0000000000000625","article-title":"Efficacy of Human Papillomavirus Vaccination 4 Years After Conization for High-Grade Cervical Neoplasia","volume":"25","author":"G\u00f3mez de la Rosa","year":"2021","journal-title":"J. Low. Genit. Tract Dis."},{"issue":"4","key":"10.1016\/j.ejogrb.2021.11.008_b0025","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3390\/vaccines8040717","article-title":"Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison","volume":"8","author":"Bogani","year":"2020","journal-title":"Vaccines."},{"issue":"3","key":"10.1016\/j.ejogrb.2021.11.008_b0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ijc.32752","article-title":"Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status","volume":"147","author":"Sand","year":"2020","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.ejogrb.2021.11.008_b0035","first-page":"402","article-title":"Impact of the human papillomavirus vaccination on patients who underwent conization for high- grade cervical intraepithelial neoplasia","volume":"40","author":"Ortega-Qui\u00f1onero","year":"2019","journal-title":"Eur J Gynaecol Oncol."},{"issue":"12","key":"10.1016\/j.ejogrb.2021.11.008_b0040","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/ijc.30391","article-title":"HPV PATRICIA Study Group, Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"Int. J. Cancer."},{"issue":"2","key":"10.1016\/j.ejogrb.2021.11.008_b0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2018.08.033","article-title":"SPERANZA project: HPV vaccination after treatment for CIN2","volume":"151","author":"Ghelardi","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ejogrb.2021.11.008_b0050","doi-asserted-by":"crossref","first-page":"212.e1","DOI":"10.1016\/j.ajog.2016.02.021","article-title":"Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment","volume":"215","author":"Hildesheim","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ejogrb.2021.11.008_b0055","doi-asserted-by":"crossref","first-page":"e1401","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ejogrb.2021.11.008_b0060","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2\u20133)?","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ejogrb.2021.11.008_b0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/vaccines8010045","article-title":"Efficacy of HPV Vaccination in Women Receiving LEEP for Cervical Dysplasia: A Single Institution\u2019s Experience","volume":"8","author":"Petrillo","year":"2020","journal-title":"Vaccines."},{"issue":"6","key":"10.1016\/j.ejogrb.2021.11.008_b0070","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00404-018-4926-y","article-title":"Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease","volume":"298","author":"Pieralli","year":"2018","journal-title":"Arch. Gynecol. Obstet."},{"issue":"2","key":"10.1016\/j.ejogrb.2021.11.008_b0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/vaccines8020245","article-title":"HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions","volume":"8","author":"del Pino","year":"2020","journal-title":"Vaccines."},{"issue":"8","key":"10.1016\/j.ejogrb.2021.11.008_b0080","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3390\/vaccines9080816","article-title":"HPV Vaccination in Women Treated for Cervical Intraepithelial Neoplasia: A Budget Impact Analysis","volume":"9","author":"Basile","year":"2021","journal-title":"Vaccines."},{"issue":"48","key":"10.1016\/j.ejogrb.2021.11.008_b0085","doi-asserted-by":"crossref","first-page":"20458","DOI":"10.1073\/pnas.0908502106","article-title":"The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding","volume":"106","author":"Kines","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejogrb.2021.11.008_b0090","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/jnci\/djr061","article-title":"Effect of Pap Smear Collection and Carrageenan on Cervicovaginal Human Papillomavirus-16 Infection in a Rhesus Macaque Model","volume":"103","author":"Roberts","year":"2011","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.ejogrb.2021.11.008_b0095","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan","volume":"13","author":"Roberts","year":"2007","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.ejogrb.2021.11.008_b0100","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"1","key":"10.1016\/j.ejogrb.2021.11.008_b0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Indian HPV Vaccine Study Group, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncol."},{"issue":"32","key":"10.1016\/j.ejogrb.2021.11.008_b0110","first-page":"4783","article-title":"Indian HPV vaccine study group, Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer?","volume":"36","author":"Sankaranarayanan","year":"2018","journal-title":"Early findings from an Indian study, Vaccine."},{"key":"10.1016\/j.ejogrb.2021.11.008_b0115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/djx158","article-title":"Durability of Protection Afforded by Fewer Doses of the HPV16\/18 Vaccine: The CVT Trial","volume":"110","author":"Safaeian","year":"2018","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.ejogrb.2021.11.008_b0120","first-page":"1302","volume":"38","author":"Whitworth","year":"2020","journal-title":"Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials, Vaccine"},{"key":"10.1016\/j.ejogrb.2021.11.008_b0125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/B978-0-12-814457-2.00019-2","article-title":"Clinical Trials of Human Papillomavirus Vaccines","author":"Paavonen","year":"2020","journal-title":"Human Papillomavirus"},{"issue":"48","key":"10.1016\/j.ejogrb.2021.11.008_b0130","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12\u201326 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine."}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211521005522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211521005522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:55:16Z","timestamp":1759557316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211521005522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":26,"alternative-id":["S0301211521005522"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2021.11.008","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2021.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}